Markers of systemic inflammation and apo-AI containing HDL subpopulations in women with and without diabetes

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Russo, Giuseppina T ^a   Giandalia, Annalisa ^a   Romeo, Elisabetta L ^a   Alibrandi, Angela ^b   Horvath, Katalin V ^c   Asztalos, Bela F ^c   Cucinotta, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84935016916     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/607924     Document Type: Article

References (59)

1. J. A. Raza, R. A. Reinhart, and A.Movahed, "Ischemic heart disease in women and the role of hormone therapy," International Journal of Cardiology, vol. 96, no. 1, pp. 7-19, 2004.
2. E. Barrett-Connor, "Sex differences in coronary heart disease: Why are women so superior? The 1995 Ancel Keys Lecture," Circulation, vol. 95, no. 1, pp. 252-264, 1997.
3. J. R. Sowers, "Diabetes mellitus and cardiovascular disease in women," Archives of Internal Medicine, vol. 158, no. 6, pp. 617-621, 1998.
4. W. B. Kannel and P. W. F. Wilson, "Risk factors that attenuate the female coronary disease advantage," Archives of Internal Medicine, vol. 155, no. 1, pp. 57-61, 1995.
5. B. F. Asztalos, C. H. Sloop, L. Wong, and P. S. Roheim, "Twodimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations," Biochimica et Biophysica Acta, vol. 1169, no. 3, pp. 291-300, 1993.
6. D. J. Gordon, J. L. Probstfield, R. J. Garrison et al., "Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies," Circulation, vol. 79, no. 1, pp. 8-15, 1989.
7. M.-R. Taskinen, "Diabetic dyslipidaemia: Frombasic research to clinical practice," Diabetologia, vol. 46, no. 6, pp. 733-749, 2003.
8. R. Barbaras, P. Puchois, J.-C. Fruchart, andG.Ailhaud, "Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpA-IA-II particles," Biochemical and Biophysical Research Communications, vol. 142, no. 1, pp. 63-69, 1987.
9. B. F. Asztalos and E. J. Schaefer, "HDL in atherosclerosis: Actor or bystander?" Atherosclerosis Supplements, vol. 4, no. 1, pp. 21-29, 2003.
10. B. F. Asztalos, P. S. Roheim, R. L. Milani et al., "Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 12, pp. 2670-2676, 2000.
11. M. C. Cheung, B. G. Brown, A. C.Wolf, and J. J. Albers, "Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease," Journal of Lipid Research, vol. 32, no. 3, pp. 383-394, 1991.
12. B. F. Asztalos, L. A. Cupples, S. Demissie et al., "High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 11, pp. 2181-2187, 2004.
13. M. E. Brousseau, M. R. Diffenderfer, J. S. Millar et al., "Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion,"Arteriosclerosis,Thrombosis, andVascular Biology, vol. 25, no. 5, pp. 1057-1064, 2005.
14. G. T. Russo, K. V. Horvath, A. Di Benedetto, A. Giandalia, D. Cucinotta, and B. Asztalos, "Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes," Atherosclerosis, vol. 210, no. 1, pp. 294-301, 2010.
15. B. F. Asztalos, M. Tani, and E. J. Schaefer, "Metabolic and functional relevance of HDL subspecies," Current Opinion in Lipidology, vol. 22, no. 3, pp. 176-185, 2011.
16. E. J. Schaefer and B. F. Asztalos, "Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction,"TheAmerican Journal of Cardiology, vol. 100, no. 11, pp. S25-S31, 2007.
17. B. F. Asztalos,M.De La Llera-Moya, G. E.Dallal, K. V.Horvath, E. J. Schaefer, and G. H. Rothblat, "Differential effects of HDL subpopulations on cellular ABCA1-and SR-BI-mediated cholesterol efflux," Journal of Lipid Research, vol. 46, no. 10, pp. 2246-2253, 2005.
18. B. F. Asztalos, E. J. Schaefer, K. V. Horvath et al., "Role of LCAT in HDL remodeling: Investigation of LCAT deficiency states," Journal of Lipid Research, vol. 48, no. 3, pp. 592-599, 2007.
19. A. Di Benedetto, G. T. Russo, F. Corrado et al., "Inflammatory markers in women with a recent history of gestational diabetes mellitus," Journal of Endocrinological Investigation, vol. 28, no. 1, pp. 34-38, 2005.
20. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, "C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women," The New England Journal ofMedicine, vol. 342, no. 12, pp. 836-843, 2000.
21. J. Genest, "C-reactive protein: Risk factor, biomarker and/or therapeutic target?" Canadian Journal of Cardiology, vol. 26, supplement A, pp. 41A-44A, 2010.
22. E. Corrado, M. Rizzo, G. Coppola et al., "An update on the role of markers of inflammation in atherosclerosis," Journal of Atherosclerosis and Thrombosis, vol. 17, no. 1, pp. 1-11, 2010.
23. A. M. Bennet, J. A. Prince, G.-Z. Fei et al., "Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction," Atherosclerosis, vol. 171, no. 2, pp. 359-367, 2003.
24. P. J. Klover, T. A. Zimmers, L. G. Koniaris, and R. A. Mooney, "Chronic exposure to Interleukin-6 causes hepatic insulin resistance in mice," Diabetes, vol. 52,no. 11,pp. 2784-2789, 2003.
25. C. Chrysohoou, C. Pitsavos, J. Skoumas et al., "The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population; the ATTICA study," International Journal of Cardiology, vol. 122, no. 1, pp. 29-33, 2007.
26. "The expert committee on the diagnosis and classification of diabetes mellitus report of the expert committee on the diagnosis and classification of diabetes mellitus," Diabetes Care, vol. 20, pp. 1183-1197, 1997.
27. J. R.McNamara and E. J. Schaefer, "Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions," Clinica Chimica Acta, vol. 166, no. 1, pp. 1-8, 1987.
28. T. Gordon, W. P. Castelli, M. C. Hjortland,W. B. Kannel, and T. R. Dawber, "High density lipoprotein as a protective factor against coronary heart disease. The Framingham study," The American Journal of Medicine, vol. 62, no. 5, pp. 707-714, 1977.
29. G. Assmann, P. Cullen, and H. Schulte, "The munster heart study (PROCAM). Results of follow-up at 8 years," European Heart Journal, vol. 19, pp. A2-A11, 1998.
30. P. P. Toth, M. Barylski, D. Nikolic et al., "Should low highdensity lipoprotein cholesterol (HDL-C) be treated," Best Practice and Research Clinical EndocrinologyMetabolism, vol. 28,no. 3, pp. 353-368, 2014.
31. S. J. Robins, A. Lyass, J. P. Zachariah, J. M. Massaro, and R. S. Vasan, "Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: The framingham heart study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 1208-1214, 2011.
32. Y.-X. Meng, E. S. Ford, C. Li et al., "Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US adults: Findings from national health and nutrition examination survey 1999-2002," Clinical Chemistry, vol. 53, no. 12, pp. 2152-2159, 2007.
33. G. Luc, J.-M. Bard, I. Juhan-Vague et al., "C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1255-1261, 2003.
34. S. G. Lakoski, M. Cushman, M. Criqui et al., "Gender and Creactive protein: Data fromtheMultiethnic Study of Atherosclerosis (MESA) cohort,"The American Heart Journal, vol. 152, no. 3, pp. 593-598, 2006.
35. M.-M. Lai, C.-I. Li, S. L. Kardia et al., "Sex difference in the association of metabolic syndrome with high sensitivity Creactive protein in a Taiwanese population," BMC PublicHealth, vol. 10, article 429, 2010.
36. G. Daniele, R. Guardado Mendoza, D. Winnier et al., "The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus," Acta Diabetologica, vol. 51, no. 1, pp. 123-131, 2014.
37. T. S. Han, N. Sattar, K. Williams, C. Gonzalez-Villalpando, M. E. J. Lean, and S.M. Haffner, "Prospective study of C-reactive protein in relation to thedevelopment of diabetes andmetabolic syndrome in theMexico City diabetes study," Diabetes Care, vol. 25, no. 11, pp. 2016-2021, 2002.
38. B.Thorand, J. Baumert, H. Kolb et al., "Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002," Diabetes Care, vol. 30, no. 4, pp. 854-860, 2007.
39. R.-C. Huang, T. A. Mori, V. Burke et al., "Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents," Diabetes Care, vol. 32,no. 4, pp.695-701, 2009.
40. E. M. Tsompanidi,M. S. Brinkmeier, E. H. Fotiadou, S.M.Giakoumi, and K. E. Kypreos, "HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis," Atherosclerosis, vol. 208, no. 1, pp. 3-9, 2010.
41. C. Besler, T. F. Lüscher, and U. Landmesser, "Molecular mechanisms of vascular effects ofHigh-density lipoprotein: Alterations in cardiovascular disease," EMBO Molecular Medicine, vol. 4, no. 4, pp. 251-268, 2012.
42. J. R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. V. Eckardstein, "HDL and arteriosclerosis: Beyond reverse cholesterol transport," Atherosclerosis, vol. 161, no. 1, pp. 1-16, 2002.
43. C. Radojkovic, A. Genoux, V. Pons et al., "Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 7, pp. 1125-1130, 2009.
44. G. D. Norata, A. Pirillo, E. Ammirati, and A. L. Catapano, "Emerging role of high density lipoproteins as a player in the immune system," Atherosclerosis, vol. 220, no. 1, pp. 11-21, 2012.
45. L. Camont, M. J. Chapman, and A. Kontush, "Biological activities of HDL subpopulations and their relevance to cardiovascular disease," Trends in Molecular Medicine, vol. 17, no. 10, pp. 594-603, 2011.
46. D. M. Tehrani, J. M. Gardin, D. Yanez et al., "Impact of inflammatory biomarkers on relation of high density lipoproteincholesterol with incident coronary heart disease: Cardiovascular health study," Atherosclerosis, vol. 231, no. 2, pp. 246-251, 2013.
47. B. J. Ansell, M. Navab, S. Hama et al., "Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients fromcontrol subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment," Circulation, vol. 108, no. 22, pp. 2751-2756, 2003.
48. G. K. Hansson, "Mechanisms of disease: Inflammation, atherosclerosis, and coronary artery disease,"TheNewEngland Journal of Medicine, vol. 352, no. 16, pp. 1685-1695, 2005.
49. K. Alwaili, D. Bailey, Z. Awan et al., "The HDL proteome in acute coronary syndromes shifts to an inflammatory profile," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1821, no. 3, pp. 405-415, 2012.
50. R. Kisilevsky and L. Subrahmanyan, "Serumamyloid A changes high density lipoprotein's cellular affinity: A clue to serum amyloid A's principal function," Laboratory Investigation, vol. 66, no. 6, pp. 778-785, 1992.
51. A. Kontush and M. J. Chapman, "Functionally defective highdensity lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis," Pharmacological Reviews, vol. 58, no. 3, pp. 342-374, 2006.
52. M.McMahon, J. Grossman, J. FitzGerald et al., "Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis," Arthritis and Rheumatism, vol. 54, no. 8, pp. 2541-2549, 2006.
53. M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, and A. M. Fogelman, "Mechanisms of disease: Proatherogenic HDL-An evolving field," Nature Clinical Practice Endocrinology and Metabolism, vol. 2, no. 9, pp. 504-511, 2006.
54. H.BinduG, V. S. Rao, andV.V.Kakkar, "Friendturns foe: Transformation of anti-inflammatory hdl to proinflammatory HDL during acute-phase response," Cholesterol, vol. 2011, Article ID 274629, 7 pages, 2011.
55. A. Von Eckardstein, Y. Huang, and G. Assmann, "Physiological role and clinical relevance of high-density lipoprotein subclasses," CurrentOpinion in Lipidology, vol. 5, no.6,pp. 404-416, 1994.
56. B. J.Ansell, G. C. Fonarow, and A.M. Fogelman, "The paradox of dysfunctional high-density lipoprotein," Current Opinion in Lipidology, vol. 18, no. 4, pp. 427-434, 2007.
57. T. Kelesidis, J. S. Currier, D. Huynh et al., "A biochemical fluorometric method for assessing the oxidative properties of HDL," Journal of Lipid Research, vol. 52, no. 12, pp. 2341-2351, 2011.
58. Y. L. Marcel, P. K. Weech, T. D. Nguyen, R. W. Milne, andW. J. McConathy, "Apolipoproteins as the basis for heterogeneity in high-density lipoprotein2 and high-density lipoprotein3. Studies by isoelectric focusing on agarose films," European Journal of Biochemistry, vol. 143, no. 3, pp. 467-476, 1984.
59. B. F. Asztalos, D. Collins, L. A. Cupples et al., "Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2185-2191, 2005.